Microbiotix, Inc.
Worcester, MA
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1 Innovation Dr #120C, Worcester, MA 01605, USA
- Website
- microbiotix.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $3,787,586 |
| FY2025 | $5,640,911 |
| FY2024 | $2,485,753 |
| FY2023 | $2,900,296 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $3,787,586 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Icahn School Of Medicine At Mount Sinai | R01AI185869 | $391,665 | |
| Icahn School Of Medicine At Mount Sinai | R56AI175974 | $173,090 | |
| Trustees Of Dartmouth College | R01AI181215 | $1,024,366 | |
| University Of Texas At Austin | R01AI158706 | $41,293 | |
| University Of Texas At Austin | R01AI158706 | $41,293 |
Similar vendors
About the company
Microbiotix, Inc. is a clinical-stage biopharmaceutical company located in Worcester, Massachusetts, specializing in developing innovative pharmaceutical compounds for infectious disease treatments. Registered in SAM.gov since 2005, the company focuses on creating small molecule therapeutics targeting complex viral and bacterial infections. As a for-profit corporate entity, Microbiotix works extensively with federal agencies to advance research and development of novel treatment approaches for challenging medical conditions.
Through federal contract work, Microbiotix has been engaged in developing specialized pharmaceutical interventions, particularly with the National Institute of Allergy and Infectious Diseases (NIAID). Their contract work has included developing pan-filovirus entry inhibitors, with a significant $14,195,727 cost-plus-fixed-fee contract focused on lead optimization and preclinical studies for small molecule compounds targeting viral entry mechanisms. The company has collaborated with prime contractors like Trustees of Boston University on projects addressing multi-drug resistant bacterial pathogens, specifically developing inhibitors targeting bacterial secretion systems and exploring novel therapeutic approaches for challenging infections.
Microbiotix has secured multiple federal grant awards across various research domains, primarily from agencies like NIAID, National Eye Institute, and the Defense Health Agency. Their grant portfolio includes developing treatments for diverse medical challenges such as cytomegalovirus infections, antifungal agents for mucormycosis, inhibitors for drug-resistant CMV, treatments for tick-borne diseases like Lyme and tularemia, and specialized therapies for ocular adenoviral infections. The company has engaged in collaborative sub-grant work with research institutions including Icahn School of Medicine at Mount Sinai, Trustees of Dartmouth College, and University of Texas at Austin, demonstrating a broad and sophisticated approach to pharmaceutical research and development across infectious disease domains.
Quick answers
Is Microbiotix, Inc. registered in SAM.gov?
Yes. Microbiotix, Inc.'s SAM.gov registration is active through October 14, 2027.
What is Microbiotix, Inc.'s CAGE code?
Microbiotix, Inc.'s CAGE code is 465F8, and its Unique Entity ID (UEI) is SCNKBDM341T1.
How much has Microbiotix, Inc. received in federal contracts?
Federal contracts obligated $5,640,911 to Microbiotix, Inc. in fiscal year 2025 and $14,814,546 in fiscal years 2023 through 2027.
How does Microbiotix, Inc. rank among federal contractors?
Microbiotix, Inc. ranked #33 in PSC AN12 in FY2025.
What is Microbiotix, Inc.'s most recent federal award?
Microbiotix, Inc.'s most recent federal grant award is Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections - title: novel benzyl-piperidine… (R41AI195240), from National Institute of Allergy and Infectious Diseases (NIH), on September 22, 2025.
On GovTribe
See Microbiotix, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors